Scalper1 News
Clovis Oncology (CLVS) shares rose in after-hours trading on ovarian cancer news, one of several notable biotech announcements late Monday. Clovis announced that the Food and Drug Administration has given its rucaparib agent as a “breakthrough therapy” as sole treatment for advanced ovarian cancer patients. That means the FDA will give it an accelerated review. Clovis could seek FDA approval in 2016. Shares rose 7.4% to 73.74 in late trading on Scalper1 News
Scalper1 News